BLinatumomab and iNKT in Relapsed B-Cell ALL
BLinatumomab and iNKT in Relapsed B-Cell ALL
Not yet recruiting · NCT07869368 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BLinatumomab and iNKT in Relapsed B-Cell ALL | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Disease Progression, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07869368 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| MiNK Therapeutics | 2 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 243 |